pembrolizumab + sEphB4-HSA

Pembrolizumab + sEphB4-HSA is an investigational combination therapy for cancer, particularly studied in solid tumors such as metastatic urothelial carcinoma and head and neck squamous cell carcinoma (HNSCC). Pembrolizumab is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, thereby enhancing anti-tumor immune responses. sEphB4-HSA is a recombinant human fusion protein composed of the extracellular domain of EphB4 fused to human serum albumin; it binds specifically to the ligand EphrinB2, blocking bidirectional signaling between tumor cells and tumor vasculature. This blockade inhibits angiogenesis, reduces tumor growth, and promotes immune cell infiltration into tumors. The combination has shown favorable safety and promising efficacy in early-phase clinical trials, especially among patients with HPV-negative/EphrinB2-positive HNSCC or metastatic urothelial carcinoma refractory to platinum-based chemotherapy[1][2][3][5][6].

Other names

soluble EphB4-human serum albumin fusion proteinrecombinant EphB4-HSA fusion protein